Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF, Tandon M. Udwadia ZF, et al. Among authors: barkate h. Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16. Int J Infect Dis. 2021. PMID: 33212256 Free PMC article. Clinical Trial.
An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions.
Joshi S, Gudi G, Menon VCA, Tandon M, Joshi V, Suryawanshi S, Barkate H, Sawant N, Katare S, Siddique W. Joshi S, et al. Among authors: barkate h. Clin Pharmacokinet. 2020 Mar;59(3):349-357. doi: 10.1007/s40262-019-00819-4. Clin Pharmacokinet. 2020. PMID: 31583610 Clinical Trial.
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M, Aravind SR, Thacker H, Paramesh S, Mohan B, Chawla M, Asirvatham A, Goyal R, Shembalkar J, Balamurugan R, Kadam P, Alva H, Kodgule R, Tandon M, Vaidyanathan S, Pendse A, Gaikwad R, Katare S, Suryawanshi S, Barkate H. Dharmalingam M, et al. Among authors: barkate h. Drugs. 2020 Apr;80(6):587-600. doi: 10.1007/s40265-020-01285-0. Drugs. 2020. PMID: 32162274 Free PMC article. Clinical Trial.
Role of favipiravir in the treatment of COVID-19.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Joshi S, et al. Among authors: barkate h. Int J Infect Dis. 2021 Jan;102:501-508. doi: 10.1016/j.ijid.2020.10.069. Epub 2020 Oct 30. Int J Infect Dis. 2021. PMID: 33130203 Free PMC article. Review.
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
Udwadia ZF, Barkate H, Patil S, Rangwala S, Wu W, Caracta CF, Tandon M. Udwadia ZF, et al. Among authors: barkate h. Int J Infect Dis. 2021 Apr;105:686-687. doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15. Int J Infect Dis. 2021. PMID: 33601032 Free PMC article. No abstract available.
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial.
Salvi S, Balki A, Krishnamurthy S, Panchal S, Patil S, Kodgule R, Khandagale H, Pendse A, Wu W, Rangwala S, Tandon M, Barkate H. Salvi S, et al. Among authors: barkate h. ERJ Open Res. 2021 Jul 26;7(3):00255-2021. doi: 10.1183/23120541.00255-2021. eCollection 2021 Jul. ERJ Open Res. 2021. PMID: 34322547 Free PMC article.
52 results